Protein S-100B : a prognostic marker for cerebral damage / Mark Stroick, Marc Fatar, Andreas Ragoschke-Schumm, Klaus Fassbender, Thomas Bertsch, Michael G. Hennerici
The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - 13(2006), 25, Seite 3053-3060 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stroick, Mark Gregor, 1974- [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Animals |
|---|
| Anmerkungen: |
Gesehen am 06.05.2022 |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.2174/092986706778521751 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
180108288X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 180108288X | ||
| 003 | DE-627 | ||
| 005 | 20230427140245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220506s2006 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/092986706778521751 |2 doi | |
| 035 | |a (DE-627)180108288X | ||
| 035 | |a (DE-599)KXP180108288X | ||
| 035 | |a (OCoLC)1341459561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stroick, Mark Gregor |d 1974- |e verfasserin |0 (DE-588)124641946 |0 (DE-627)575608684 |0 (DE-576)294426094 |4 aut | |
| 245 | 1 | 0 | |a Protein S-100B |b a prognostic marker for cerebral damage |c Mark Stroick, Marc Fatar, Andreas Ragoschke-Schumm, Klaus Fassbender, Thomas Bertsch, Michael G. Hennerici |
| 264 | 1 | |c 2006 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.05.2022 | ||
| 520 | |a The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data. | ||
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Blood-Brain Barrier | |
| 650 | 4 | |a Brain Injuries | |
| 650 | 4 | |a Brain Ischemia | |
| 650 | 4 | |a Cell Hypoxia | |
| 650 | 4 | |a Cerebral Hemorrhage | |
| 650 | 4 | |a Cerebrovascular Disorders | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a S100 Proteins | |
| 650 | 4 | |a Trauma Severity Indices | |
| 700 | 1 | |a Fatar, Marc |d 1972- |e verfasserin |0 (DE-588)12250108X |0 (DE-627)705931501 |0 (DE-576)293298963 |4 aut | |
| 700 | 1 | |a Ragoschke-Schumm, Andreas |d 1971- |e verfasserin |0 (DE-588)123914213 |0 (DE-627)706472330 |0 (DE-576)293940258 |4 aut | |
| 700 | 1 | |a Faßbender, Klaus |e verfasserin |0 (DE-588)1230477322 |0 (DE-627)1752917693 |4 aut | |
| 700 | 1 | |a Bertsch, Thomas |e verfasserin |0 (DE-588)105441193X |0 (DE-627)791504999 |0 (DE-576)410254835 |4 aut | |
| 700 | 1 | |a Hennerici, Michael G. |d 1948- |e verfasserin |0 (DE-588)11587545X |0 (DE-627)077527704 |0 (DE-576)290126444 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 1996 |g 13(2006), 25, Seite 3053-3060 |h Online-Ressource |w (DE-627)325051623 |w (DE-600)2034240-8 |w (DE-576)273880209 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2006 |g number:25 |g pages:3053-3060 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.2174/092986706778521751 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | u | w | |d 13 |j 2006 |e 25 |h 3053-3060 |g 8 |
| 951 | |a AR | ||
| 952 | |d 13 |j 2006 |e 25 |h 3053-3060 |g 8 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4129906526 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 06-05-22 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2006 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_6 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_8 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1752313097 |a Stroick, Mark Gregor | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416468684 |a Neurologische Klinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1445200597 |a Fatar, Marc | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416468684 |a Neurologische Klinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)175291791X |a Ragoschke-Schumm, Andreas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416467254 |a Medizinische Fakultät Mannheim | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_3 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1752917766 |a Faßbender, Klaus | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416468684 |a Neurologische Klinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_4 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1480254908 |a Bertsch, Thomas | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1416467254 |a Medizinische Fakultät Mannheim | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_5 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1440038317 |a Hennerici, Michael G. | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416468684 |a Neurologische Klinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416467254 |a Medizinische Fakultät Mannheim | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_6 | ||